TRAF3IP2 mediates high glucose-induced endothelin-1 production as well as endothelin-1-induced inflammation in endothelial cells

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 314, Issue 1, 2018, Pages H52-H64

  Padilla, Jaume ^a,b   Carpenter, Andrea J ^c   Das, Nitin A ^c   Kandikattu, Hemanth Kumar ^a,d   López Ongil, Susana ^e,f   Martinez Lemus, Luis A ^a,b   Siebenlist, Ulrich ^g   DeMarco, Vincent G ^a,d   Chandrasekar, Bysani ^a,b,d  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^f IRSIN   (Spain)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Endothelial dysfunction; Endothelin 1; Hyperglycemia; TRAF3 interacting protein 2

Indexed keywords

2 (2 CHLOROPHENYL) 4 [3 (DIMETHYLAMINO)PHENYL] 5 METHYL 1H PYRAZOLO[4,3 C]PYRIDINE 3,6(2H,5H) DIONE; ADAPTOR PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; GLUCOSE; HYDROGEN PEROXIDE; I KAPPA B KINASE BETA; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PLATELET ENDOTHELIAL CELL ADHESION MOLECULE 1; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE; TRAF3 INTERACTING PROTEIN 2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID; CELL ADHESION MOLECULE; CYTOKINE; I KAPPA B KINASE; IKBKB PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; STRESS ACTIVATED PROTEIN KINASE 1; TRAF3IP2 PROTEIN, HUMAN; TRAF3IP2 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTIC ENDOTHELIAL CELL; ARTICLE; CELL ADHESION; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOLECULAR MECHANICS; MONOCYTE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED; COCULTURE; DIABETIC ANGIOPATHY; DRUG EFFECT; ENDOTHELIUM CELL; EXPERIMENTAL DIABETES MELLITUS; GENETICS; METABOLISM; NONOBESE DIABETIC MOUSE; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL ADHESION; CELL ADHESION MOLECULES; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; ENDOTHELIAL CELLS; ENDOTHELIN-1; FEMALE; GLUCOSE; HUMANS; I-KAPPA B KINASE; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MICE, INBRED NOD; MITOGEN-ACTIVATED PROTEIN KINASE 8; MONOCYTES; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PEPTIDES AND PROTEINS;

EID: 85043476464     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00478.2017     Document Type: Article

References (53)

1. Adamopoulos C, Piperi C, Gargalionis AN, Dalagiorgou G, Spilioti E, Korkolopoulou P, Diamanti-Kandarakis E, Papavassiliou AG. Advanced glycation end products upregulate lysyl oxidase and endothelin-1 in human aortic endothelial cells via parallel activation of ERK1/2-NF-kappaB and JNK-AP-1 signaling pathways. Cell Mol Life Sci 73: 1685– 1698, 2016. doi:10.1007/s00018-015-2091-z.
2. Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, Reudelhuber TL, Schiffrin EL. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 110: 2233–2240, 2004. doi:10.1161/01.CIR. 0000144462.08345.B9.
3. Aroor AR, Habibi J, Kandikattu HK, Garro-Kacher M, Barron B, Chen D, Hayden MR, Whaley-Connell A, Bender SB, Klein T, Padilla J, Sowers JR, Chandrasekar B, DeMarco VG. Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice. Cardiovasc Diabetol 16: 61, 2017. doi:10.1186/s12933-017-0544-4.
4. Babaei S, Picard P, Ravandi A, Monge JC, Lee TC, Cernacek P, Stewart DJ. Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation. Cardiovasc Res 48: 158–167, 2000. doi:10.1016/S0008-6363(00)00169-3.
5. Bansilal S, Farkouh ME, Fuster V. Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol 99: 6B–14B, 2007. doi:10.1016/j.amjcard.2006.11.002.
6. Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J 34: 2444–2452, 2013. doi:10.1093/eurheartj/eht142.
7. A receptor blockade in patients with atherosclerosis. Clin Sci 102: 321–327, 2002.
8. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 8: 29, 2010. doi:10.1186/1478-7954-8-29.
9. Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 106: 1783–1787, 2002. doi:10.1161/01.CIR.0000032260.01569.64.
10. Ceriello A. Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes. Eur J Cardiovasc Prev Rehab 17, Suppl 1: S15–S19, 2010. doi:10.1097/01.hjr. 0000368193.24732.66.
11. B receptor, NADPH oxidase and caveolin-1. Br J Pharmacol 145: 323–333, 2005. doi:10.1038/sj.bjp.0706193.
12. Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, Morawietz H. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun 269: 713–717, 2000. doi:10.1006/bbrc. 2000.2354.
13. Fiorentino TV, Prioletta A, Zuo P, Folli F. Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Des 19: 5695–5703, 2013. doi:10.2174/1381612811319320005.
14. Gogg S, Smith U, Jansson PA. Increased MAPK activation and impaired insulin signaling in subcutaneous microvascular endothelial cells in type 2 diabetes: the role of endothelin-1. Diabetes 58: 2238–2245, 2009. doi:10. 2337/db08-0961.
15. Guan Q, Liu W, Liu Y, Fan Y, Wang X, Yu C, Zhang Y, Wang S, Liu J, Zhao J, Gao L. High glucose induces the release of endothelin-1 through the inhibition of hydrogen sulfide production in HUVECs. Int J Mol Med 35: 810–814, 2015. doi:10.3892/ijmm.2014.2059.
16. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag 3: 853–876, 2007.
17. A receptor blockade. Circ Res 89: 969–976, 2001. doi:10.1161/hh2301.100980.
18. Hansen NW, Hansen AJ, Sams A. The endothelial border to health: Mechanistic evidence of the hyperglycemic culprit of inflammatory disease acceleration. IUBMB Life 69: 148–161, 2017. doi:10.1002/iub.1610.
19. Khamaisi M, Dahan R, Hamed S, Abassi Z, Heyman SN, Raz I. Role of protein kinase C in the expression of endothelin converting enzyme-1. Endocrinology 150: 1440–1449, 2009. doi:10.1210/en.2008-0524.
20. Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med 249: 225–235, 2001. doi:10.1046/j.1365-2796.2001.00789.x.
21. Leonardi A, Chariot A, Claudio E, Cunningham K, Siebenlist U. CIKS, a connection to Ikappa B kinase and stress-activated protein kinase. Proc Natl Acad Sci USA 97: 10494–10499, 2000. doi:10.1073/pnas. 190245697.
22. Leung JW, Wong WT, Koon HW, Mo FM, Tam S, Huang Y, Vanhoutte PM, Chung SS, Chung SK. Transgenic mice over-expressing ET-1 in the endothelial cells develop systemic hypertension with altered vascular reactivity. PLoS One 6: e26994, 2011. doi:10.1371/journal.pone. 0026994.
23. Li MW, Mian MO, Barhoumi T, Rehman A, Mann K, Paradis P, Schiffrin EL. Endothelin-1 overexpression exacerbates atherosclerosis and induces aortic aneurysms in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 33: 2306–2315, 2013. doi:10.1161/ATVBAHA.113. 302028.
24. Li X, Commane M, Nie H, Hua X, Chatterjee-Kishore M, Wald D, Haag M, Stark GR. Act1, an NF-kappa B-activating protein. Proc Natl Acad Sci USA 97: 10489–10493, 2000. doi:10.1073/pnas.160265197.
25. Liu C, Qian W, Qian Y, Giltiay NV, Lu Y, Swaidani S, Misra S, Deng L, Chen ZJ, Li X. Act1, a U-box E3 ubiquitin ligase for IL-17 signaling. Sci Signal 2: ra63, 2009. doi:10.1126/scisignal.2000382.
26. López-Ongil S, Saura M, Zaragoza C, Gónzalez-Santiago L, Rodríguez-Puyol M, Lowenstein CJ, Rodríguez-Puyol D. Hydrogen peroxide regulation of bovine endothelin-converting enzyme-1. Free Radic Biol Med 32: 406–413, 2002. doi:10.1016/S0891-5849(01)00822-X.
27. Mahmoud AM, Szczurek MR, Blackburn BK, Mey JT, Chen Z, Robinson AT, Bian JT, Unterman TG, Minshall RD, Brown MD, Kirwan JP, Phillips SA, Haus JM. Hyperinsulinemia augments endothelin-1 protein expression and impairs vasodilation of human skeletal muscle arterioles. Physiol Rep 4: e12895, 2016. doi:10.14814/phy2.12895.
28. Manea SA, Manea A, Heltianu C. Inhibition of JAK/STAT signaling pathway prevents high-glucose-induced increase in endothelin-1 synthesis in human endothelial cells. Cell Tissue Res 340: 71–79, 2010. doi:10.1007/s00441-010-0936-1.
29. Manea SA, Todirita A, Manea A. High glucose-induced increased expression of endothelin-1 in human endothelial cells is mediated by activated CCAAT/enhancer-binding proteins. PLoS One 8: e84170, 2013. doi:10.1371/journal.pone.0084170.
30. Martínez-Miguel P, Medrano-Andrés D, Griera-Merino M, Ortiz A, Rodríguez-Puyol M, Rodríguez-Puyol D, López-Ongil S. Tweak up-regulates endothelin-1 system in mouse and human endothelial cells. Cardiovasc Res 113: 207–221, 2017. doi:10.1093/cvr/cvw239.
31. Martínez-Miguel P, Raoch V, Zaragoza C, Valdivielso JM, Rodríguez-Puyol M, Rodríguez-Puyol D, López-Ongil S. Endothelin-converting enzyme-1 increases in atherosclerotic mice: potential role of oxidized low density lipoproteins. J Lipid Res 50: 364–375, 2009. doi:10.1194/jlr. M800215-JLR200.
32. Mellbin LG, Anselmino M, Rydén L. Diabetes, prediabetes and cardiovascular risk. Eur J Cardiovasc Prev Rehabil 17, Suppl 1: S9–S14, 2010. doi:10.1097/01.hjr.0000368192.24732.2f.
33. Mummidi S, Das NA, Carpenter AJ, Kandikattu H, Krenz M, Siebenlist U, Valente AJ, Chandrasekar B. Metformin inhibits aldosterone-induced cardiac fibroblast activation, migration and proliferation in vitro, and reverses aldosterone>salt-induced cardiac fibrosis in vivo. J Mol Cell Cardiol 98: 95–102, 2016. doi:10.1016/j.yjmcc.2016.07.006.
34. Nakagami H, Kaneda Y, Ogihara T, Morishita R. Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis. Curr Diabetes Rev 1: 59–63, 2005. doi:10.2174/1573399052952550.
35. Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it isor is it? Lancet 350, Suppl 1: SI4–SI9, 1997. doi:10.1016/S0140-6736(97)90021-0.
36. Nishiyama SK, Zhao J, Wray DW, Richardson RS. Vascular function and endothelin-1: tipping the balance between vasodilation and vasoconstriction. J Appl Physiol 122: 354–360, 2017. doi:10.1152/japplphysiol. 00772.2016.
37. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 34: 2436–2443, 2013. doi:10.1093/eurheartj/eht149.
38. Paneni F, Lüscher TF. Cardiovascular protection in the treatment of type 2 diabetes: a review of clinical trial results across drug classes. Am J Med 130: S18–S29, 2017. doi:10.1016/j.amjmed.2017.04.008.
39. Park JY, Takahara N, Gabriele A, Chou E, Naruse K, Suzuma K, Yamauchi T, Ha SW, Meier M, Rhodes CJ, King GL. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 49: 1239–1248, 2000. doi:10.2337/diabetes.49.7.1239.
40. Pernow J, Shemyakin A, Böhm F. New perspectives on endothelin-1 in atherosclerosis and diabetes mellitus. Life Sci 91: 507–516, 2012. doi:10. 1016/j.lfs.2012.03.029.
41. Rafnsson A, Shemyakin A, Pernow J. Selective endothelin ETA and dual ET(A)/ET(B) receptor blockade improve endothelium-dependent vasodilatation in patients with type 2 diabetes and coronary artery disease. Life Sci 118: 435–439, 2014. doi:10.1016/j.lfs.2014.02.026.
42. Reynolds LJ, Credeur DP, Manrique C, Padilla J, Fadel PJ, Thyfault JP. Obesity, type 2 diabetes, and impaired insulin-stimulated blood flow: role of skeletal muscle NO synthase and endothelin-1. J Appl Physiol 122: 38–47, 2017. doi:10.1152/japplphysiol.00286.2016.
43. Roberts AC, Porter KE. Cellular and molecular mechanisms of endothelial dysfunction in diabetes. Diab Vasc Dis Res 10: 472–482, 2013. doi:10.1177/1479164113500680.
44. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115–126, 1999. doi:10.1056/NEJM199901143400207.
45. Symons JD, Rendig SV, Fu LW, Longhurst JC. Endothelin-1 limits increases in blood flow to native and collateral-dependent myocardium. Am J Physiol 273: R41–R48, 1997.
46. Tang ST, Su H, Zhang Q, Tang HQ, Wang CJ, Zhou Q, Wei W, Zhu HQ, Wang Y. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBβ system through the activation of AMP-activated protein kinase. Int J Mol Med 37: 1558–1566, 2016. doi:10.3892/ijmm.2016.2578.
47. Valente AJ, Irimpen AM, Siebenlist U, Chandrasekar B. OxLDL induces endothelial dysfunction and death via TRAF3IP2: inhibition by HDL3 and AMPK activators. Free Radic Biol Med 70: 117–128, 2014. doi:10.1016/j.freeradbiomed.2014.02.014.
48. Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol (Oxf) 219: 22–96, 2017. doi:10.1111/apha.12646.
49. Venkatesan B, Valente AJ, Das NA, Carpenter AJ, Yoshida T, Dela-fontaine JL, Siebenlist U, Chandrasekar B. CIKS (Act1 or TRAF3IP2) mediates high glucose-induced endothelial dysfunction. Cell Signal 25: 359–371, 2013. doi:10.1016/j.cellsig.2012.10.009.
50. Watson AM, Li J, Schumacher C, de Gasparo M, Feng B, Thomas MC, Allen TJ, Cooper ME, Jandeleit-Dahm KA. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 53: 192–203, 2010. doi:10.1007/s00125-009-1540-3.
51. Widlansky ME, Gokce N, Keaney JF, Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42: 1149–1160, 2003. doi:10.1016/S0735-1097(03)00994-X.
52. Yamauchi T, Ohnaka K, Takayanagi R, Umeda F, Nawata H. Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells. FEBS Lett 267: 16–18, 1990. doi:10.1016/0014-5793(90)80276-O.
53. Yariswamy M, Yoshida T, Valente AJ, Kandikattu HK, Sakamuri SS, Siddesha JM, Sukhanov S, Saifudeen Z, Ma L, Siebenlist U, Gardner JD, Chandrasekar B. Cardiac-restricted overexpression of TRAF3 interacting protein 2 (TRAF3IP2) results in spontaneous development of myocardial hypertrophy, fibrosis, and dysfunction. J Biol Chem 291: 19425–19436, 2016. doi:10.1074/jbc.M116.724138.